Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CS 1001

Drug Profile

CS 1001

Alternative Names: CS1001; WBP 3155

Latest Information Update: 09 Jan 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator CStone Pharmaceuticals
  • Developer Blueprint Medicines; CStone Pharmaceuticals
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Programmed cell death-1 ligand-1 inhibitors; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Gastric cancer; Non-small cell lung cancer; Oesophageal cancer
  • Phase II Hodgkin's disease; T-cell lymphoma
  • Phase I/II Liver cancer
  • Phase I Solid tumours

Most Recent Events

  • 08 Jan 2020 CStone Pharmaceuticals initiates the phase III GEMSTONE-304 trial for Oesophageal cancer (Combination therapy, First-line therapy, Inoperable/unresectable, Late stage disease, Recurrent, Metastatic disease) in China (IV) (NCT04187352)
  • 08 Jan 2020 Phase-I/II clinical trials in Liver cancer (Late-stage disease, Metastatic disease, Inoperable/Unresectable, Combination therapy) in China (IV) (NCT04194801)
  • 20 Dec 2019 CStone Pharmaceuticals completes a phase I trial for Solid tumors in China
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top